Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients.

Daniel BoakyeLina JansenNiels HalamaJenny Chang-ClaudeMichael HoffmeisterHermann Brenner

Published in: Therapeutic advances in medical oncology (2021)

EDChemo is common in stage III colon cancer patients receiving chemotherapy and more than half of the cases of EDChemo and dose reduction are due to adverse treatment effects. Further research should address the potential for reducing EDChemo and dose reduction rates by close monitoring of patients for early signs and enhanced management of adverse effects, especially gastrointestinal events.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
emergency department
risk assessment
radiation therapy
locally advanced
combination therapy
human health
rectal cancer
electronic health record
drug induced